MTOR and lung carcinoma: We also found strong correlation across cell lines between the dependency to PPRC1 and mTOR-inhibitors (temsirolimus, used in the treatment of renal cancer), dual PI3K/mTOR-inhibitors (dactolisib, in clinical trial for advanced solid tumors (Wise-Draper et al., 2017)), YK-4–279 (showing pre-clinical efficacy for Ewing sarcoma (Lamhamedi-Cherradi et al., 2015)) and the chemotherapy agent docetaxel, currently used in the treatment of breast, lung cancer, stomach cancer, head and neck and prostate cancer.